Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03907488
Title Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
Recruitment Suspended
Gender both
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)

Hodgkin's lymphoma, lymphocytic depletion

Hodgkin's lymphoma, nodular sclerosis

Hodgkin's lymphoma

Hodgkin's lymphoma, mixed cellularity

Hodgkin's lymphoma, lymphocytic-histiocytic predominance



Brentuximab vedotin + Dacarbazine + Doxorubicin + Vinblastine


Dacarbazine + Doxorubicin + Nivolumab + Vinblastine

Age Groups: adult | child | senior
Covered Countries USA | CAN

No variant requirements are available.